Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion

Ci Capital's Rating of Calliditas Therapeutics AB (publ) on 8/18/2020

On August 18, 2020, Ci Capital updated its outlook on Calliditas Therapeutics AB (publ) (NASDAQ:CALT) with the action "Reiterated Rating", keeping a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Ci Capital

DateCompanyAction
3/27/2026
BRP Inc. stock logo
DOO
BRP
Lower Price Target
2/11/2026
Lundin Mining Co. stock logo
LUN
Lundin Mining
Boost Price Target
11/18/2024
MDA Space Ltd. stock logo
MDA
MDA Space
Boost Price Target
1/17/2023
Topaz Energy Corp. stock logo
TPZ
Topaz Energy
Lower Price Target
8/12/2021
Freehold Royalties Ltd. stock logo
FRU
Freehold Royalties
Boost Price Target
9/14/2020
InflaRx N.V. stock logo
IFRX
InflaRx
Reiterated Rating
More Ratings From Ci Capital